INTRODUCTION

Obesity is a major health problem associated with serious comorbidities, including type II diabetes. Diet and lifestyle modifications are often difficult to adhere to and thus ineffective over long periods. High-protein diets suppress food intake and reduce weight gain or increase weight loss. The expression of the promiscuous amino-acid-sensing receptors, the umami taste receptor T1R1/T1R3, the G-protein-coupled receptor family C group 6 member A and the calcium-sensing receptor (CaSR) in the gastrointestinal (GI) tract has led to the suggestion that they may sense amino acids in protein digestion to modulate satiety. There is in vivo evidence that these receptors may be involved in gut nutrient sensing, but their role in nutrient sensing and satiety in vivo has been little investigated.

The CaSR is named for its well-characterised role in calcium homeostasis, but in fact this receptor regulates a number of cellular processes, including cell proliferation and differentiation. Calcium is the major activating ligand, but the CaSR also allosterically binds aromatic L-amino acids and, less potently, aliphatic amino acids.

L-Phenylalanine (L-Phe) is a proteinogenic and essential aromatic amino acid derived from dietary intake and the recycling of amino-acid stores in the body. L-Phe is utilised in protein synthesis, tyrosine synthesis and as a substrate in other biochemical pathways. L-Phe is the most potent amino-acid activator of the CaSR. The CaSR is expressed on hormone-secreting enteroendocrine cells, leading to suggestions that it may sense amino acids within the GI tract to modulate gut hormone release. L-Phe stimulates the release of cholecystokinin (CCK) from STC-1 cells, and L-Phe and L-tryptophan stimulate CCK secretion from isolated L-cells. In addition, specific L-amino acids, including L-Phe, stimulate the release of the energy and glucose homeostasis-regulating gut hormones peptide YY (PYY), glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide from isolated rat small intestine through a CaSR-dependent mechanism. However, to date, the role of CaSR in hormone release, or glucose or energy homeostasis has not been studied in vivo. We thus investigated the effects of L-Phe on food intake and body weight, energy expenditure, gut hormone release and glucose tolerance, and the role of the CaSR in mediating these effects in rodents.

METHODS: We investigated the effects of the aromatic amino-acid and calcium-sensing receptor (CaSR) agonist L-phenylalanine (L-Phe) on food intake and the release of the gastrointestinal (GI) hormones peptide YY (PYY), glucagon-like peptide-1 (GLP-1) and ghrelin in rodents, and the role of the CaSR in mediating these effects in vitro and in vivo. We also examined the effect of oral L-Phe administration on glucose tolerance in rats.

RESULTS: Oral administration of L-Phe acutely reduced food intake in rats and mice, and chronically reduced food intake and body weight in diet-induced obese mice. Ileal L-Phe also reduced food intake in rats. L-Phe stimulated GLP-1 and PYY release, and reduced plasma ghrelin, and also stimulated insulin release and improved glucose tolerance in rats. Pharmacological blockade of the CaSR attenuated the anorectic effect of intra-ileal L-Phe in rats, and L-Phe-induced GLP-1 release from STC-1 and primary L cells was attenuated by CaSR blockade.

CONCLUSIONS: L-Phe reduced food intake, stimulated GLP-1 and PYY release, and reduced plasma ghrelin in rodents. Our data provide evidence that the anorectic effects of L-Phe are mediated via the CaSR, and suggest that L-Phe and the CaSR system in the GI tract may have therapeutic utility in the treatment of obesity and diabetes. Further work is required to determine the physiological role of the CaSR in protein sensing in the gut, and the role of this system in humans.

ORIGINAL ARTICLE

L-phenylalanine modulates gut hormone release and glucose tolerance, and suppresses food intake through the calcium-sensing receptor in rodents

A Alamshah, E Spreckley, M Norton, JS Kinsey-Jones, A Amin, A Ramgulam, Y Cao, R Johnson, K Saleh, E Akalestou, Z Malik, N Gonzalez-Abuin, A Jomard, R Amarsi, A Moolla, PR Sargent, GW Gray, SR Bloom and KG Murphy

OBJECTIVE: High-protein diets (HPDs) are associated with greater satiety and weight loss than diets rich in other macronutrients. The exact mechanisms by which HPDs exert their effects are unclear. However, evidence suggests that the sensing of amino acids produced as a result of protein digestion may have a role in appetite regulation and satiety. We investigated the effects of L-phenylalanine (L-Phe) on food intake and glucose homeostasis in rodents.

METHODS: We investigated the effects of the aromatic amino-acid and calcium-sensing receptor (CaSR) agonist L-phenylalanine (L-Phe) on food intake and the release of the gastrointestinal (GI) hormones peptide YY (PYY), glucagon-like peptide-1 (GLP-1) and ghrelin in rodents, and the role of the CaSR in mediating these effects in vitro and in vivo. We also examined the effect of oral L-Phe administration on glucose tolerance in rats.

RESULTS: Oral administration of L-Phe acutely reduced food intake in rats and mice, and chronically reduced food intake and body weight in diet-induced obese mice. Ileal L-Phe also reduced food intake in rats. L-Phe stimulated GLP-1 and PYY release, and reduced plasma ghrelin, and also stimulated insulin release and improved glucose tolerance in rats. Pharmacological blockade of the CaSR attenuated the anorectic effect of intra-ileal L-Phe in rats, and L-Phe-induced GLP-1 release from STC-1 and primary L cells was attenuated by CaSR blockade.

CONCLUSIONS: L-Phe reduced food intake, stimulated GLP-1 and PYY release, and reduced plasma ghrelin in rodents. Our data provide evidence that the anorectic effects of L-Phe are mediated via the CaSR, and suggest that L-Phe and the CaSR system in the GI tract may have therapeutic utility in the treatment of obesity and diabetes. Further work is required to determine the physiological role of the CaSR in protein sensing in the gut, and the role of this system in humans.
MATERIALS AND METHODS

Animals
Male Wistar rats (200–250 g; Charles River, Margate, UK) and male C57BL/6 mice, 8–10 weeks (Harlan, Bicester, UK) were individually housed under controlled temperature (21–23 °C) and humidity on a 12 h light:12 h darkness cycle. All animals had ad libitum access to standard chow RM1 (SDS, Witham, UK) and water unless stated otherwise. All animal procedures were in accordance with the UK Home Office Animals (Scientific Procedures) Act 1986 and approved by the Animal Welfare and Ethics Review Board at the Central Biological Services unit at the Hammersmith Campus of Imperial College London.

Feeding studies
Rats and mice were acclimatised to the experimental procedures and randomised by body weight. Rats and mice were fasted for 16 h overnight and subsequently received an oral gavage (OG; 3 ml of vehicle (10% TWEN20 in water) or L-Phe (Sigma, Poole, UK) at doses stated in the results in the early hours of the light phase. For dark-phase-feeding studies, rats and mice had ad libitum access to food and were administered agents at the onset of dark phase. For intra-ileal administration studies, rats received 0.5 ml of vehicle or 10 mg·kg−1 L-Phe; a concentration previously shown to stimulate GLP-1 and PYY release from isolated rat intestinal loops and of a similar order of magnitude to the levels of L-Phe in the plasma of rats given 15 mg·kg−1 L-Phe or 15 mmol·kg−1 L-Phe (Sigma, Poole, UK) were used according to the manufacturers’ instructions. Radioimmunoassays were performed following overnight fasting and were used to determine plasma hormone concentrations. 

Glucose tolerance test
Intraperitoneal glucose tolerance test (IPGTT) was performed following OG of L-Phe in rats. Rats were fasted overnight before receiving an intraperitoneal injection of 20% glucose (2 g·kg−1) followed by an immediate OG of vehicle (10% TWEN20 in water) or 6 mmol·kg−1 L-Phe (n = 15). A dose of 6 mmol·kg−1 was used as it resulted in a greater effect on food intake than 3 mmol·kg−1 ad libitum-fed rats. Blood samples were taken from the tail vein immediately before glucose injection (t = 0) and at 15, 30, 60, 90 and 120 min following administration, and blood glucose measured using a 65 glucometer (Contour meter and test strips, Bayer, Berkshire, UK).Insulin levels were measured at 30 min. 

Glucagon-like peptide 1
Glucagon-like peptide 1 (GLP-1) was measured in plasma samples collected as described above. 

Hormone measurement
Rat/mouse active ghrelin enzyme-linked immunosorbent assay, insulin radioimmunoassay, leptin enzyme-linked immunosorbent assay, and CCK enzyme immunoassay kits (Sigma, Poole, UK) were used according to the manufacturers’ instructions. GLP-1 and PYY were measured using previously described in-house radioimmunoassays. 

Chronic feeding studies
Male mice 6–8 weeks of age were group-housed (n = 5 per cage) with ad libitum access to water and 60% high-fat diet (Research Diets, New Brunswick, NJ, USA) for 8 weeks. Mice were then individually housed and given 1 week to acclimatise before experiments. Mice received an OG of vehicle (10% TWEN20 in water) or 12 mmol·kg−1 L-Phe twice throughout each dark phase for four nights, and three times for each of the three subsequent nights (n = 10). Body weight and food intake were measured daily at the beginning of dark phase and 1 h following the first daily gavage. Mice were decapitated 24 h following the last administration of L-Phe and plasma collected and stored as described above. 

Hormone measurement
Rat/mouse active ghrelin enzyme-linked immunosorbent assay, insulin radioimmunoassay, leptin enzyme-linked immunosorbent assay, and CCK enzyme immunoassay kits (Millipore, Darmstadt, Germany) were used according to the manufacturers’ instructions. GLP-1 and PYY were measured using previously described in-house radioimmunoassays.
L-Phe reduces food intake in rodents

We investigated the anorectic effect of intra-ileal and oral L-Phe administration in rodents. Both GLP-1 and PYY are highly expressed in the ileum, and the ileum may have a role in the greater satiety observed following a high-protein meal. Intra-ileal administration of 10 mm L-Phe significantly reduced food intake in ad libitum-fed rats during the 0–1 h interval during dark phase (P < 0.01, n = 9, crossover; Figure 1a). Furthermore, oral administration of L-Phe significantly decreased food intake in both rats and mice (Figures 1b and f). In fasted rats, OG of 3 mmol kg\(^{-1}\) L-Phe significantly reduced food intake compared to the control at 0–1, 2–4 and 0–4 h intervals following administration in the light phase (n = 13, vehicle; 11, L-Phe; Figure 1b). OG of 6 mmol kg\(^{-1}\) L-Phe significantly reduced food intake in ad libitum-fed rats 0–1, 0–2 and 0–4 h following administration at the onset of the dark phase (n = 10; Figure 1d). Similarly, OG of 12 mmol kg\(^{-1}\) L-Phe in fasted mice significantly reduced cumulative food intake 0–1, 0–2 and 0–4 h following administration during the light phase compared to vehicle (n = 5; Figure 1c). In ad libitum-fed mice, OG of 6 mmol kg\(^{-1}\) L-Phe significantly reduced food intake in mice 0–1, 1–2 and 0–2 h post administration in the dark phase (n = 10; Figure 1e). In addition, OG of 12 mmol kg\(^{-1}\) L-Phe reduced food intake in diet-induced obese (DIO) mice during 0–1 h period post administration (P < 0.01, n = 10; Figure 1f).

L-Phe increases energy expenditure in rats

OG of 6 mmol kg\(^{-1}\) L-Phe reduced food intake in rats in comprehensive laboratory animal-monitoring system metabolic cages during the 0–120 min interval (AUC: P < 0.05 vs control, n = 8; Figure 2a), though without effect at later time points (Figure 2b). OG of 6 mmol kg\(^{-1}\) L-Phe increased the maximal oxygen consumption (VO\(_2\)) and the maximal carbon dioxide production (VCO\(_2\)); this effect achieved statistical significance for VO\(_2\) during the 0–120 min interval following administration (AUC VO\(_2\): P < 0.05 vs control; Figures 2c and d). Respiratory exchange ratio was also lower in L-Phe-treated rats during 0–120 min following administration (Figure 2e). OG of 6 mmol kg\(^{-1}\) L-Phe had no significant effect on locomotor activity (Figure 2f).

L-Phe stimulates GI hormone release

L-Phe (30 mm) increased GLP-1 release by ~9-fold from STC-1 cells (n = 9 independent plates; Figure 3a), and 10 and 100 mm L-Phe significantly stimulated the release of GLP-1 from a murine primary colonic L-cell culture (n = 6 independent plates from 6 mice; Figure 3b). Similarly, 50 and 100 mm L-Phe significantly stimulated PYY release (n = 9 independent plates from 9 mice; Figure 3c).

L-Phe improves glucose tolerance in rats

L-Phe is a potent agonist of the CaSR,\(^{32}\) which has previously been implicated in amino-acid-induced gut hormone release.\(^{7,22}\) CaSR is highly expressed and co-localised within GLP-1 and PYY secreting L cells.\(^{19}\) The expression of CaSR was detected in all levels of the GI tract in mice (Supplementary Figure S1). We hypothesised that the anorectic effect of L-Phe may be mediated via the CaSR. Oral administration of the synthetic CaSR agonist R568.HCl significantly reduced food intake during 0–1 h compared to the vehicle (P < 0.05, n = 8, vehicle; 9, R568; Figure 5a). Given that it was unclear where oral L-Phe was acting in the GI tract, and that high doses of a CaSR antagonist might affect systemic calcium homeostasis, we investigated the ability of a low dose of the CaSR antagonist NPS2143.HCl to block the anorectic effects of low dose intra-ileal L-Phe. The anorectic effect of intra-ileal administration of L-Phe was attenuated by the co-administration of NPS2143.HCl (P < 0.05, n = 18, crossover; Figure 5b). In addition, L-Phe-induced GLP-1 release from a murine primary colonic crypt culture was not significant in the presence of a CaSR antagonist, and L-Phe-induced GLP-1 release from STC-1 cells and murine ileal organoids was significantly attenuated by CaSR antagonists (Figures 5c–e).

Repeate L-Phe administration reduces food intake and body weight in mice

We investigated whether the anorectic effects of L-Phe could be sustained chronically and affect body weight in DIO mice, a widely used model of obesity. Repeated twice daily oral administration of 12 mmol kg\(^{-1}\) L-Phe over 4 days had no significant effect on food intake or body weight in DIO mice. However, subsequent three times daily administration of 12 mmol kg\(^{-1}\) L-Phe significantly reduced cumulative food intake in DIO mice on days 6 and 7, and body weight on days 5, 6 and 7 (n = 10; Figures 6a and b). Furthermore, repeated OG of 12 mmol kg\(^{-1}\) L-Phe significantly reduced plasma leptin levels in DIO mice compared to the controls (Figure 6c), suggesting that the reduced body weight reflected at least partly a loss of body fat. Chronic L-Phe administration also resulted in significantly increased plasma glucose levels following an IPGTT in rats treated with L-Phe (P < 0.05 vs control; Figures 2c and d). Respiratory exchange ratio was also lower in L-Phe-treated rats during 0–120 min following administration (Figure 2e). OG of 6 mmol kg\(^{-1}\) L-Phe had no significant effect on locomotor activity (Figure 2f).

L-Phe is a potent agonist of the CaSR,\(^{32}\) which has previously been implicated in amino-acid-induced gut hormone release.\(^{7,22}\) CaSR is highly expressed and co-localised within GLP-1 and PYY secreting L cells.\(^{19}\) The expression of CaSR was detected in all levels of the GI tract in mice (Supplementary Figure S1). We hypothesised that the anorectic effect of L-Phe may be mediated via the CaSR. Oral administration of the synthetic CaSR agonist R568.HCl significantly reduced food intake during 0–1 h compared to the vehicle (P < 0.05, n = 8, vehicle; 9, R568; Figure 5a). Given that it was unclear where oral L-Phe was acting in the GI tract, and that high doses of a CaSR antagonist might affect systemic calcium homeostasis, we investigated the ability of a low dose of the CaSR antagonist NPS2143.HCl to block the anorectic effects of low dose intra-ileal L-Phe. The anorectic effect of intra-ileal administration of L-Phe was attenuated by the co-administration of NPS2143.HCl (P < 0.05, n = 18, crossover; Figure 5b). In addition, L-Phe-induced GLP-1 release from a murine primary colonic crypt culture was not significant in the presence of a CaSR antagonist, and L-Phe-induced GLP-1 release from STC-1 cells and murine ileal organoids was significantly attenuated by CaSR antagonists (Figures 5c–e).

Repeate L-Phe administration reduces food intake and body weight in mice

We investigated whether the anorectic effects of L-Phe could be sustained chronically and affect body weight in DIO mice, a widely used model of obesity. Repeated twice daily oral administration of 12 mmol kg\(^{-1}\) L-Phe over 4 days had no significant effect on food intake or body weight in DIO mice. However, subsequent three times daily administration of 12 mmol kg\(^{-1}\) L-Phe significantly reduced cumulative food intake in DIO mice on days 6 and 7, and body weight on days 5, 6 and 7 (n = 10; Figures 6a and b). Furthermore, repeated OG of 12 mmol kg\(^{-1}\) L-Phe significantly reduced plasma leptin levels in DIO mice compared to the controls (Figure 6c), suggesting that the reduced body weight reflected at least partly a loss of body fat. Chronic L-Phe administration also resulted in significantly increased plasma glucose levels following an IPGTT in rats treated with L-Phe (P < 0.05 vs control; Figures 2c and d). Respiratory exchange ratio was also lower in L-Phe-treated rats during 0–120 min following administration (Figure 2e). OG of 6 mmol kg\(^{-1}\) L-Phe had no significant effect on locomotor activity (Figure 2f).
ghrelin levels \( P < 0.05, n = 10; \) Figure 6d), and a trend towards increased plasma GLP-1 and PYY levels (GLP-1: \( P = 0.1; \) PYY: \( P = 0.19 \) vs controls; Figures 6e and f).

**DISCUSSION**

Evidence suggests that the satiety associated with high-protein diets may be mediated by sensing of the amino-acid constituents of protein, rather than by the sensing of the protein itself.\(^3\) L-Phe is an essential amino-acid abundant in dietary protein that activates the CaSR, a promiscuous amino-acid-sensing receptor expressed in the GI tract. The effects of L-Phe on appetite have been little studied, and the anorectic effects of intra-ileal administration of L-Phe on food intake in rodents have not previously been described.\(^34,35\) Our studies demonstrate that L-Phe suppresses appetite and increases energy expenditure in rodents. Chronic L-Phe administration in DIO mice reduced food intake and body weight. L-Phe significantly stimulated GLP-1 release \textit{in vitro} and \textit{in vivo}, and improved glucose tolerance \textit{in vivo}. Furthermore, we provide novel evidence of a role for the CaSR in the gut in the regulation of food intake as the anorectic effects of intra-ileal L-Phe were blocked by co-administration of a CaSR antagonist, and the L-Phe-stimulated release of GLP-1 from STC-1 cells was attenuated by a CaSR antagonist. Together these data provide evidence that pharmacological activation of the CaSR in the gut can modulate food intake, and suggest that the CaSR may have a role in sensing the amino-acid products of protein digestion to regulate appetite.
The anorectic effects of individual amino acids in rodents have recently been described. Jordi et al. examined the effects of oral administration of amino acids, including L-Phe, on food intake at a dose of 6.7 mmol kg\(^{-1}\) and found no significant effect on food intake. In contrast, our data demonstrate that oral administration of L-Phe at 3 mmol kg\(^{-1}\) robustly reduces food intake in fasted rats, and at doses between 6 and 12 mmol kg\(^{-1}\) reduces food intake in mice in the early light phase, and in ad libitum-fed rats and mice in the early dark phase. Mice required a relatively higher dose (12 mmol kg\(^{-1}\)) of L-Phe to achieve a comparable reduction in food intake to rats. The doses of L-Phe orally administered in our feeding studies are pharmacological, but similar to the amount of L-Phe ingested daily by a rodent on a 45% protein diet. The anorectic effect observed is beyond that attributable to the caloric value of the given L-Phe solution. For example, a dose of 6 mmol kg\(^{-1}\) L-Phe is equivalent to ~1.54 kcal per rat, but resulted in a 4.81 kcal reduction in food intake; the observed reduction is still significant if these additional kilocalories are added to the energy intake of the treatment group. Oral L-Phe administration increased energy expenditure in rats, an effect that may be driven by increased locomotor activity, though the increase in locomotor activity observed did not itself achieve statistical significance.

Oral administration of the CaSR agonist R568.HCl significantly reduced food intake in rats, and direct ileal administration of 10 mM L-Phe in conscious rats significantly reduced food intake when injected in the dark phase, an effect that was attenuated by co-administration of the CaSR antagonist NPS.2143.HCl. This concentration of L-Phe has previously been demonstrated to stimulate the release of gut hormones from isolated rat small intestinal preparations, an effect also attenuated by a CaSR antagonist. These observations suggest a role for the CaSR in mediating the effects of L-Phe on food intake.

Previous studies have demonstrated that L-Phe can stimulate CCK release, and the release of PYY and GLP-1 from isolated loops of rat small intestine. Furthermore, in vitro evidence has suggested that the L-Phe-induced CCK release from STC-1 cells and the L-Phe-induced GLP-1 and PYY release from isolated small intestine are mediated by the CaSR. In accord with these observations, treating STC-1 cells or ileal organoids with a CaSR antagonist attenuated L-Phe-induced GLP-1 release from STC-1 cells. However, treatment of cells with the antagonist resulted in only a partial reduction in GLP-1 release, suggesting that other mechanisms may also be involved in L-Phe-induced GLP-1 release. L-Phe can also activate the T1R1–T1R3 receptor, and a recent study demonstrated that L-Phe-stimulated CCK release from STC-1 cells requires the activity of the T1R1–T1R3 receptor. However, our findings suggest that L-Phe mediates its effects on gut hormone release at least in part via the CaSR.
Oral L-Phe reduced acylated ghrelin levels in rats. We have previously shown that L-cysteine reduces food intake in rats, an effect that may in part be due to a reduction in acylated ghrelin levels observed following oral administration. The CaSR is enriched in ghrelin cells of the stomach and CaSR activation by calcium chloride and R568.HCl inhibited ghrelin release from primary gastric mucosal cells in vitro. Interestingly, chronic L-Phe administration significantly increased circulating ghrelin levels. Plasma ghrelin levels are reduced in obese individuals and elevated following weight loss, an effect thought to represent a feedback loop intended to increase food intake when body weight drops. The increase in ghrelin observed thus likely reflects the reduced body weight of these animals, rather than a specific effect of L-Phe. However, this increase in ghrelin does suggest that the reduction in food intake and the consequent weight loss are unlikely to be driven by changes in ghrelin signalling. Further studies investigating the effects of repeated administration of L-Phe over a longer time period are required to determine whether tolerance develops to its effects and to further assess the likely utility of such an approach to treat obesity.

Oral administration of L-Phe in rats significantly elevated circulating GLP-1 levels, and raised PYY levels, though this effect...
Figure 5. The role of CaSR in mediating the anorectic effect of L-Phe. (a) The effect of oral administration vehicle (1.85% dimethyl sulfoxide (DMSO) in water) and 1.1 mg kg⁻¹ R568.HCl in overnight-fasted rats at 0–1 h following administration during early hours of light phase (n = 8, vehicle; 9, L-Phe; P < 0.05 vs control); and (b) the effect of intra-ileal administration of vehicle (0.25 DMSO, 0.9% saline), 1 μM NPS.2143.HCl, 10 μM L-Phe, or 10 μM L-Phe and 1 μM NPS2143.HCl on food intake in rats with ad libitum access to food injected at the beginning of dark phase at 0–1 h post administration (n = 18, crossover). (c) The effect of 50 μM L-Phe in presence or absence of 10 μM NPS2143.HCl on GLP-1 release from STC-1 cells following 2 h incubation, n = 8 independent plates. (d) The effect of 30 μM L-Phe in presence or absence of 15 μM NPS2390 on GLP-1 release from primary mice colonic L cells following 2 h incubation, n = 5 independent plates. (e) The effect of 30 μM L-Phe in presence or absence of 15 μM NPS2390 on GLP-1 release from mouse ileal organoids following 24 h incubation, n = 8, L-Phe; 9, NPS2390, control; 10, L-Phe+NPS2390, independent organoid cultures. ***P < 0.001 vs control; ****P < 0.0001 vs control; ##P < 0.01, ###P < 0.001 vs L-Phe. All data presented as mean ± s.e.m.

did not achieve statistical significance. L-Phe has previously been shown to stimulate GLP-1 release from murine primary colonic L cells. Direct administration of L-Phe into the ileum increased plasma PYY in rats, though this effect did not reach statistical significance (P = 0.06). Interestingly, direct ileal administration did not alter plasma GLP-1 levels (data not shown). In humans, CaSR is highly expressed in the distal small intestine and a significant population of L cells express CaSR in the proximal colon. GLP-1 is expressed throughout the GI tract, whereas PYY-expressing cells are relatively scarce in the upper small intestine, and much more common in the distal small intestine and colon. Oral administration of L-Phe may stimulate GLP-1 release from enteroendocrine cells in the proximal gut, whereas direct ileal administration may stimulate PYY-secreting L cells. L-Phe stimulated the release of GLP-1 and PYY from a murine primary colonic L-cell culture, and of GLP-1 from STC-1 cells. It is therefore interesting that direct ileal administration did not influence circulating GLP-1 levels. Recent evidence suggests that GLP-1 and PYY are packaged in different secretory granules within L cells, raising the possibility that the release of these hormones can be differentially regulated. Alternatively, only specific PYY-expressing populations of L cells in the ileum may respond to L-Phe.

L-Phe has previously been found to stimulate CCK release both in vitro and in vivo, but we did not observe this effect in our studies. However, previous studies either used considerably higher doses or concentrations of L-Phe, or the L-Phe was administered in the form of a di-peptide. It is also possible that the single 30 min time point we used missed an effect on CCK release. Chronic L-Phe administration in DIO mice did not result in statistically significant differences in circulating GLP-1 or PYY levels, though concentrations were higher than that in vehicle-treated controls. This may reflect that the animals had not received L-Phe for 24 h; L-Phe may largely have acute effects on the release of these hormones.

Specific amino acids are known to influence glucose homeostasis. L-Arginine stimulates the release of insulin from pancreatic β-cells, and -glutamine, a GLP-1 secretagogue in vitro, stimulates insulin and improves glucose homeostasis in obese and diabetic human subjects. Given that oral L-Phe elevated plasma GLP-1 levels in rats, we hypothesised that it would also influence glucose homeostasis. In accord with this, oral L-Phe significantly increased insulin release and improved glucose tolerance in response to an IPGTT in rats. Further work is required to identify whether this effect is exclusively mediated by the effects of L-Phe on GLP-1 release; CaSR is also expressed on pancreatic beta cells, and the effects observed feasibly reflect direct effects on insulin release. A recent study has demonstrated improved glucose tolerance in rats following activation of the gut CaSR system by synthetic peptide agonists.

In summary, our data suggest that sensing of L-Phe in the GI tract can modulate hormone release, glucose tolerance and appetite, and demonstrate for the first time that L-Phe can act via the CaSR to reduce food intake in vivo. Though it has been speculated that promiscuous G-protein-coupled amino-acid receptors in the gut may regulate feeding behaviour, our study represents the first time that amino-acid sensing by such a receptor in the GI tract has been demonstrated to influence food
intake. While pharmacological, our findings may represent activation of a physiological nutrient sensing system. Further work is required to determine the role of the CaSR in the sensing of dietary protein, and the utility of exploiting L-Phe and the Gi CaSR system in the treatment of obesity and diabetes.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
We thank Olga Boruc, MRC CSC for technical assistance with the comprehensive laboratory animal-monitoring system. This paper presents independent research funded by BBSRC, MRC, Innovate UK (Technology Strategy Board) and the Society for Endocrinology. The views expressed are those of the author(s) and not necessarily those of the funders. The Section of Endocrinology and Investigative Medicine is supported by the NIHR Biomedical Research Centre Funding Scheme. AA was funded by grants from the MRC, BBSRC, NIHR, an Integrative Mammalian Biology (IMIB) Capacity Building Award and an FP7 HEALTH-2009-241592 EuroCHIP grant, and is supported by the NIHR Biomedical Research Centre Funding Scheme. AA was funded by Innovate UK (Technology Strategy Board), ES was funded by an NC3Rs studentship, MN was funded by the Imperial College Ghateli Studentship, JK-J was funded by the BBSRC and A Amin was funded by an MRC Clinical Research Training Fellowship.

AUTHOR CONTRIBUTIONS
A Alamshah designed and performed the experiments, analysed the data and wrote the manuscript. ES, MN and JK-J performed experiments and analysed the data. AA, RJ, KS, EA and ZM assisted with experiments. AM assisted in the study design and performed experiments. PRS, GWG and SRB provided material and technical support. KGM wrote the manuscript and was responsible for study concept, design and analysis.

REFERENCES
1 Emerging Risk Factors C, Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 2011; 377: 1085–1095.
2 Vazquez G, Duval S, Jacobs DR Jr, Silventoinen K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. Epidemiol Rev 2007; 29: 115–128.
3 Poppitt SD, McCormack D, Biffenstein R. Short-term effects of macronutrient preloads on appetite and energy intake in lean women. Physiol Behav 1998; 64: 279–285.
4 Hochstenbach-Waalen A, Veldhorst MA, Nieuwendaalhuizen AG, Westerterp-Plantenga MS, Westerterp KR. Comparison of 2 diets with either 25% or 10% of energy as casein on energy expenditure, substrate balance, and appetite profile. Am J Clin Nutr 2009; 89: 831–838.
5 Wellendorph P, Johansen LD, Brauner-Osborne H. Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients. Mol Pharmacol 2009; 76: 453–465.
6 Wellendorph P, Johansen LD, Brauner-Osborne H. The emerging role of promiscuous 7TM receptors as chemosensors for food intake. Vitam Horm 2010; 84: 151–184.
7 Daly K, Al-Rammahi M, Moran A, Marcello M, Ninomiya Y, Shirazi-Beechey SP. Sensing of amino acids by the gut-expressed taste receptor T1R1-T1R3 stimulates CCK secretion. Am J Physiol Gastrointest Liver Physiol 2013; 304: G271–G282.
8 Diakonkaiaki E, Pais R, Tolhurst G, Parker HE, Hurscroft J, Rauscher B et al. Oligopeptides stimulate glucagon-like peptide-1 secretion in mice through proton-coupled uptake and the calcium-sensing receptor. Diabetologia 2013; 56: 2688–2696.
9 Oya M, Kitaguchi T, Pais R, Reimann F, Gribble F, Tsuboi T. The G protein-coupled receptor family C group 6 subtype A (GPRC6A) receptor is involved in amino acid-induced glucagon-like peptide-1 secretion from GLUTag cells. J Biol Chem 2013; 288: 4513–4521.
10 Kinsey-Jones JS, Alamshah A, McCavigan AK, Spreckley E, Banks K, Cereceda Manteoiva N et al. GPRC6a is not required for the effects of a high-protein diet on body weight in mice. Obesity 2015; 23: 1194–1200.
11 Riccardi D, Kemp PJ. The calcium-sensing receptor beyond extracellular calcium homeostasis: conception, development, adult physiology, and disease. Annu Rev Physiol 2012; 74: 271–297.
12 Riccardi D, Brown EM. Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am J Physiol Renal Physiol 2010; 298: F485–F499.
13 Alfadda T, Saleh AM, Houllier P, Geibel JP. Calcium-sensing receptor 20 years later. Am J Physiol Cell Physiol 2014; 307: C221–C231.
14 Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001; 81: 239–297.
Conigrave AD, Frankis AH, Brown EM, Quinn SJ. L-amino acid sensing by the calcium-sensing receptor: a general mechanism for coupling protein and calcium metabolism. Eur J Clin Nutr 2002; 56: 1072–1080.

Young VR, Pellett PL. Protein intake and requirements with reference to diet and health. Am J Clin Nutr 1987; 45 (5 Suppl): 1323–1343.

Williams RA, Marmotte CD, Burnett JR. Phenylethanoluria: an inborn error of phe-nylalanine metabolism. Clin Biochem Rev 2008; 29: 31–41.

Conigrave AD, Quinn SJ, Brown EM. L-amino acid sensing by the extracellular Ca2+ sensing receptor. Proc Natl Acad Sci USA 2000; 97: 4814–4819.

Symonds EL, Peiris M, Page AJ, Chia B, Dogra H, Masding A et al. Mechanisms of activation of mouse and human enteroendocrine cells by nutrients. Gut 2015; 64: 618–626.

Hira T, Nakajima S, Eto Y, Hara H. Calcium-sensing receptor mediates phenylalanine-induced cholecystokinin secretion in enteroendocrine STC-1 cells. FEBS J 2008; 275: 4620–4626.

Wang Y, Chandra R, Samsa LA, Gooch B, Fee BE, Cook JM et al. Amino acids stimulate cholecystokinin release through the Ca2+–sensing receptor. Am J Physiol Gastrointest Liver Physiol 2011; 300: G528–G537.

Mace OJ, Schindler M, Patel S. The regulation of K- and L-cell activity by GLUT2 and the calcium-sensing receptor CasR in rat small intestine. J Physiol 2012; 590 (Pt 12): 2917–2936.

Cho CY, Bayley HS. Amino acid composition of digesta taken from swine receiving diets containing soybean or rapeseed meals as sole source of protein. Can J Physiol Pharmacol 1972; 50: 513–522.

Murakami Y, Furuya Y, Wada M, Sakai T, Nagano N. Pharmacological properties of the calcimimetic compound NPS R-568 in vitro and in vivo. Clin Exp Nephrol 2000; 4: 293–299.

Semjonous NM, Smith KL, Parkinson JR, Gunner DJ, Liu YL, Murphy KG et al. Coordinated changes in energy intake and expenditure following hypothalamic administration of neuropeptides involved in energy balance. Coordinated changes in energy intake and expenditure following hypothalamic administration of neuropeptides involved in energy balance. Int J Obesity 2009; 33: 775–785.

Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. Glucose sensing in L cells: a primary cell study. Cell Metab 2008; 8: 532–539.

Psichas A, Sleeth ML, Murphy KG, Brooks L, Bewick GA, Hanyaloglu AC et al. The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J Obesity 2015; 39: 424–429.

Sato T, Vries RG, Snippe HJ, van de Wetering M, Barker N, Stange DE et al. Single Lgr5 stem cells build crypt–villus structures in vitro without a mesenchymal niche. Nature 2009; 459: 262–265.

Kreyiem B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 1987; 2: 1300–1304.

Adrian TE, Ferri GL, Bacaress-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89: 1070–1077.

Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409–1439.

Smajilovic S, Wellendorph P, Brauner-Osborne H. Promiscuous seven transmembrane receptors sensing L-alpha-amino acids. Curr Pharm Des 2014; 20: 2693–2702.

Veldhorst M, Smeets A, Soenen S, Hochstenbach-Waalen A, Hursel R, Diepvens K et al. Protein-induced satiety: effects and mechanisms of different proteins. Physiol Behav 2008; 94: 300–307.

Bialik RJ, LI ET, Geoffray P, Anderson GH. Route of delivery of phenylalanine influences its effect on short-term food intake in adult male rats. J Nutr 1989; 119: 1519–1527.

Jordi J, Herzog B, Camargo SM, Boyle CN, Lutz TA, Verrey F. Specific amino acids inhibit food intake via the area postrema or vagal afferents. J Physiol 2013; 591 (Pt 22): 5611–5621.

McGavigan AK, O’Hara HC, Amin A, Kinsey-Jones J, Spreckley E, Alamshah A et al. L-cysteine suppresses ghrelin and reduces appetite in rodents and humans. Int J Obesity 2015; 39: 447–455.

Ballinger AB, Clark ML. L-phenylalanine releases cholecystokinin (CCK) and is associated with reduced food intake in humans: evidence for a physiological role of CCK in control of eating. Metabolism 1994; 43: 735–738.

Brennan SC, Davies TS, Scheppelmann M, Riccardi D. Emerging roles of the extracellular calcium-sensing receptor in nutrient sensing: control of taste modulation and intestinal hormone secretion. Br J Nutr 2014; 111 (Suppl 1): S16–S22.

Tschop M, Weyer C, Tatarannia PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707–709.

Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Delling EP et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623–1630.

Tolhurst G, Zheng Y, Parker HE, Habib AM, Reimann F, Gribble FM. Glutamine triggers and potentiates glucagon-like-peptide-1 secretion by raising cytosolic Ca2+ and cAMP. Endocrinology 2011; 152: 405–413.

Cho HJ, Robinson ES, Rivera LR, McMillan PJ, Testro A, Nikfarjam M et al. Glucagon-like peptide 1 and peptide YY are in separate storage organelles in enteroendocrine cells. Cell Tissue Res 2014; 357: 63–69.

Meyer JH, Kelly GA, Jones RS. Canine pancreatic response to intrinsically perfused oligopeptides. Am J Physiol 1976; 231: 678–681.

Meyer JH, Kelly GA, Spingola LJ, Jones RS. Canine gut receptors mediating pancreatic responses to luminal L-amino acids. Am J Physiol 1976; 231: 669–677.

Floyd JC Jr., Fajans SS, Conn JW, Knoof RF, Rull J. Stimulation of insulin secretion by amino acids. J Clin Invest 1966; 45: 1487–1502.

Adegah E, Ponery AS, El-Sharkawy T, Parvez H. L-ariginine stimulates insulin secretion from the pancreas of normal and diabetic rats. Amino Acids 2001; 21: 205–209.

Greenfield JR, Farooqi IS, Keogh JM, Henning E, Habib AM, Blackwood A et al. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr 2009; 89: 106–113.

Samocha-Bonet D, Chisholm DJ, Gribble FM, Coster AC, Carpenter KH, Jones GR et al. Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study. PLoS ONE 2014; 9: e113366.

Jones PM, Kitsou-Mylona I, Gray E, Squires PE, Persaud SJ. Expression and function of the extracellular calcium-sensing receptor in pancreatic beta-cells. Arch Physiol Biochem 2007; 113: 98–103.

Muramatsu M, Hira T, Mitsunaga A, Sato E, Nakajima S, Kitahara Y et al. Activation of the gut calcium-sensing receptor by peptide agonists reduces rapid elevation of plasma glucose in response to oral glucose load in rats. Am J Physiol Gastrointest Liver Physiol 2014; 306: C1099–C1107.